Bausch + Lomb Corporation BLCO
Regular-session close
After hours · Nov 20, 7:23 PM ET
- YTD
- +13.47%
- 1 year
- +33.10%
5D -1.86 (-8.76%)
- Market cap
- 6.93B
- Revenue (ttm)
- 5.42B
- Profit margin
- -2.05%
- EPS (ttm)
- -0.32
- Shares out
- 357.50M
- Forward P/E
- 16.37
- YTD return
- +13.47%
- 1-year return
- +33.10%
- 50-day average
- 18.23
- 200-day average
- 16.94
- Volume
- 872.06K
- Avg volume
- 650.80K
- Open
- 20.24
- Previous close
- 20.69
- Day's range
- 19.30 – 20.50
- 52-week range
- 14.56 – 21.37
- Beta
- 0.52
- Analysts
- Buy
- Price target
- 21.93 (+13.2%)
- Earnings date
- Feb 17, 2027
Key statistics
- Enterprise value
- 12.05B
- PEG ratio
- 0.89
- Price / sales
- 1.28
- Price / book
- 1.08
- Revenue growth
- 7.30%
- Free cash flow
- 404.38M
- Total cash
- 513.00M
- Total debt
- 5.10B
- Return on equity
- -1.58%
- Short % of float
- 5.64%
Fundamental scorecard
6 of 25 checks passed on BLCO’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 18.00
- Target (mean)
- 21.93
- Target (high)
- 27.00
- Strong buy2
- Buy4
- Hold8
- Sell0
- Strong sell1
Next earnings
Feb 17, 2027
Expected Feb 17, 2027. Consensus EPS estimate 0.37207.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 17, 2027 | Dec 30, 2026 | 0.36 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.2145 | 0.34 | +0.13 | +58.51% |
| Jul 29, 2026 | Jun 30, 2026 | 0.1544 | 0.16 | +0.01 | +3.63% |
| Apr 29, 2026 | Mar 31, 2026 | 0.06 | 0.08 | +0.02 | +33.33% |
| Feb 18, 2026 | Dec 31, 2025 | 0.35 | 0.32 | -0.03 | -8.57% |
| Oct 29, 2025 | Sep 30, 2025 | 0.16 | 0.18 | +0.02 | +12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 29, 2026 | JP Morgan | main | Neutral | Neutral |
| Oct 29, 2026 | Citigroup | main | Buy | Buy |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 29, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 7, 2026 | Barclays | init | — | Overweight |
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Canada
- Website
- bausch.com
News
Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript
Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early Relief
Bausch + Lomb eye-drop drug misses mid-stage study main goal Bausch + Lomb Reports Phase 2 Results For BL1332; Primary Endpoint Missed, Exploratory Analyses Show Pain Relief And Faster Corneal Healing
Are Medical Stocks Lagging Bausch + Lomb (BLCO) This Year? Barclays Maintains Overweight on Bausch & Lomb, Raises Price Target to $27
Best Growth Stocks to Buy for November 17th
Best Growth Stocks to Buy for November 13th
Best Growth Stocks to Buy for November 11th
Best Growth Stocks to Buy for November 9th
Your note
Sign in to keep a note on BLCO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY AMBROSE ROBERT DOUGLAS J.D. | Officer | Stock Award(Grant) | Aug 4, 2026 | 264,241 |
| BERNIER NATHALIE D | Director | Stock Award(Grant) | May 25, 2026 | 85,505 |
| BONNEFOY LUC | Officer | Stock Award(Grant) | Aug 4, 2026 | 103,801 |
| ELDESSOUKY OSAMA A | Chief Financial Officer | Stock Award(Grant) | Aug 4, 2026 | 393,527 |
| ELDESSOUKY SAM | Chief Financial Officer | Purchase | Mar 5, 2026 | 407,130 |
| HASHAD YEHIA | Officer | Stock Award(Grant) | Aug 4, 2026 | 187,350 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Brookfield Corp /ON/ | 1.28% | 4,565,719 | 88.51M | Sep 29, 2026 |
| Shaw D.E. & Co., Inc. | 0.94% | 3,379,704 | 65.52M | Sep 29, 2026 |
| Deutsche Bank AG | 0.93% | 3,329,257 | 64.54M | Sep 29, 2026 |
| Davidson Kempner Capital Management LP | 0.88% | 3,158,972 | 61.24M | Sep 29, 2026 |
| Goldentree Asset Management LP | 0.87% | 3,106,987 | 60.23M | Sep 29, 2026 |
| Icahn Carl C | 0.66% | 2,378,100 | 46.10M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price High Yield Fund, Inc. | 0.23% | 837,050 | 16.23M | Aug 30, 2026 |
| TR PRICE-Price (T.Rowe) U.S. High Yield Trust | 0.13% | 454,220 | 8.81M | Jun 29, 2026 |
| T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Dynamic Credit Fd. | 0.06% | 204,491 | 3.96M | Jun 29, 2026 |
| T. ROWE PRICE Inst. INCOME Fd.S, INC.-T. Rowe Price Inst. High Yield F | 0.06% | 218,211 | 4.23M | Aug 30, 2026 |
| Unified Series Trust-BALLAST SMALL/MID CAP ETF | 0.04% | 147,837 | 2.87M | Jun 29, 2026 |
| Gabelli Healthcare & WellnessRx Trust | 0.04% | 144,000 | 2.79M | Sep 29, 2026 |
